Figure 3: Circulating ALDH

(A–C) The frequency of circulating ALDHhiSSClow progenitor cells co-expressing CD34 with hematopoietic/endothelial cell marker platelet endothelial cell adhesion molecule (PECAM) (CD31) was equivalent in patients with T2D compared with control subjects. (D–F) The frequency of circulating ALDHhiSSClow cells in progenitor cells co-expressing CD34 with the endothelial cell–associated marker vascular endothelial (VE)-cadherin (CD144) was decreased in patients with T2D compared with control subjects. (G–I) The frequency of circulating ALDHhiSSClow progenitor cells co-expressing CD34 with the endothelial/pericytes marker melanoma cell adhesion molecule (MCAM) (CD146) was decreased in patients with T2D compared with control subjects. Values are mean ± SEM. ∗p < 0.001 with the Student's t-test. Other abbreviations as in Figure 1.